News
- 2023/12/15
 - NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
 - 2023/10/19
 - Updated information of sustainability
 - 2023/10/18
 - Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
 - 2023/09/25
 - 
									Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody. 
											 


